Journal
LEUKEMIA & LYMPHOMA
Volume 54, Issue 2, Pages 268-276Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2012.708751
Keywords
Diffuse large B-cell lymphoma; race; disparities; outcomes; CHOP regimen; R-CHOP regimen
Categories
Funding
- Dr. Flowers' Georgia Cancer Coalition Distinguished Scientist Award
- American Society of Hematology Amos Medical Faculty Development Award
- Dr. Foran's University of Alabama at Birmingham Health Services Foundation Scholar of Excellence Award
- National Cancer Institute of the National Institutes of Health [R21CA158686]
Ask authors/readers for more resources
We performed a retrospective cohort analysis of 701 (533 white and 144 black) patients with diffuse large B-cell lymphoma (DLBCL) treated at two referral centers in southern United States between 1981 and 2010. Median age of diagnosis for blacks was 50 years vs. 57 years for whites (p < 0.001). A greater percentage of blacks presented with elevated lactate dehydrogenase levels, B-symptoms and performance status >= 2. More whites (8%) than blacks (3%) had a positive family history of lymphoma (p = 0.048). There were no racial differences in the use of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; 52% black vs. 47% white, p = 0.73). While black race predicted worse survival among patients treated with CHOP (hazard ratio [HR] 1.8, p < 0.001), treatment with R-CHOP was associated with improved survival irrespective of race (HR 0.61, p = 0.01). Future studies should examine biological differences that may underlie the observed racial differences in presentation and outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available